Loading...
•
Sep 30, 2025
Zymeworks Q3 2025 Earnings Report
Zymeworks reported its third quarter 2025 financial results with milestone-driven revenue growth but a net loss.
Key Takeaways
For Q3 2025, Zymeworks recognized total revenue of 27600000, driven by a $25.0 M milestone from Johnson & Johnson and $1.0 M in royalties, while reporting a net loss of 19600000 and diluted EPS of -0.26 as operating expenses remained elevated. Cash resources totaled 299400000 at quarter end. :contentReference[oaicite:0]{index=0}
Total revenue increased to 27600000 in Q3 2025, up from 16000000 in Q3 2024. :contentReference[oaicite:1]{index=1}
Net loss narrowed to 19600000 compared with a 29900000 loss in Q3 2024. :contentReference[oaicite:2]{index=2}
Diluted EPS was -0.26 for the quarter. :contentReference[oaicite:3]{index=3}
Cash resources of 299400000 provide runway into 2H-2027 combined with anticipated milestones. :contentReference[oaicite:4]{index=4}
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Zymeworks expects to continue advancing its clinical pipeline and partnership milestones, with cash runway anticipated into the second half of 2027 supported by existing resources and anticipated milestone receipts. :contentReference[oaicite:5]{index=5}
Positive Outlook
- Significant $25.0M milestone from Johnson & Johnson recognized in Q3 2025. :contentReference[oaicite:6]{index=6}
- Royalty revenues from Jazz and BeOne Medicines contributed to the quarter. :contentReference[oaicite:7]{index=7}
- Cash resources of 299400000 at quarter end support operations. :contentReference[oaicite:8]{index=8}
- Net loss narrowed year-over-year, indicating improved financial performance. :contentReference[oaicite:9]{index=9}
- Clinical progress with ZW191 and ZW251 ongoing. :contentReference[oaicite:10]{index=10}
Challenges Ahead
- Net loss remains significant at 19600000. :contentReference[oaicite:11]{index=11}
- Operating expenses remain high relative to revenue. :contentReference[oaicite:12]{index=12}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...